Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafolecimab + sintilimab + etoposide + carboplatin + cisplatin
- Development stage
- Unknown
- Lead developer
- Innovent Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Tafolecimab + sintilimab + etoposide + carboplatin + cisplatin is a combination therapy regimen being evaluated as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The regimen combines tafolecimab, a recombinant fully humanized monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), with sintilimab, a PD-1 checkpoint inhibitor, and standard chemotherapy (etoposide and a platinum agent, either carboplatin or cisplatin). Beyond its established role in lipid metabolism, PCSK9 inhibition is hypothesized to enhance the expression of major histocompatibility complex class I (MHC-I) on tumor cells, potentially overcoming resistance to immunotherapy and synergizing with PD-1 blockade. This multi-modal approach is currently being investigated in the STAR-SCLC trial, a Phase 2 study sponsored by the Second Affiliated Hospital of Zhejiang University.
- Brand names
- SINTBILOTyvytParaplatinPlatinol
- Other names
- STAR-SCLC regimen
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on tafolecimab + sintilimab + etoposide + carboplatin + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafolecimab + sintilimab + etoposide + carboplatin + cisplatin.